Navigation Links
Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom's Macroglobulinemia
Date:1/29/2010

Data Demonstrating a 35% Overall Response Rate with a Median Progression-Free Survival of 12.6 Months in Patients with Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia to be Published in the February 1, 2010 Issue of the Journal of Clinical Cancer Research

QUÉBEC CITY, Jan. 29 /PRNewswire-FirstCall/ - Æterna Zentaris Inc. (Nasdaq: AEZS; TSX: AEZ) (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that an article entitled "Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia," reporting Phase 2 data demonstrating the single agent activity of perifosine (KRX-0401) for the treatment of advanced Waldenstrom's Macroglobulinemia ("Waldenstrom's"), will appear in the February 1, 2010 issue of the Journal of Clinical Cancer Research. Perifosine, the Company's oral PI3K/Akt pathway inhibitor is currently being investigated in a Phase 3 trial, under Special Protocol Assessment, for the treatment of Multiple Myeloma. Like Multiple Myeloma and Non-Hodgkin's Lymphoma, Waldenstrom's is a hematologic disease in which the cancer cells target the bone marrow. There are currently no FDA approved drugs for the treatment of Waldenstrom's. Keryx Biopharmaceuticals, Inc. ( KERX) is Æterna Zentaris' partner and licensee for perifosine in the United States, Canada and Mexico. Perifosine is also out-licensed to Handok in South Korea while Æterna Zentaris retains rights for the rest of the world.

Dr. '/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer
2. Æterna Zentaris Receives NASDAQ Notification Related to Minimum Bid Price
3. AEterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia
4. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
5. AEterna Zentaris Announces Appointment of New Board Member
6. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
7. AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia
8. AEterna Zentaris Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma
9. AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
10. AEterna Zentaris Receives US$5.5 Million from Institutional Investors
11. AEterna Zentaris to Raise US$5.5 Million from Institutional Investors at US$1.20 Per Share
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 14, 2014 Carahsoft and CDS Federal ... 23, 2014 at 2pm EST (11am PST), “Natural Language ... focuses on how technology can turn raw, heterogeneous data ... government agencies. The online webinar will last approximately one ...
(Date:1/14/2014)... New York, NY (PRWEB) January 14, 2014 ... coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an ... products to serve the wound care market. , Free ... Alliqua was restructured with a seasoned management team and ...
(Date:1/14/2014)... In recent years, growing suspicion about ... product development and promotion has led to unprecedented levels ... by concerns about the insidious impact of commercialization of ... fines to the world’s biggest pharmas for illegal marketing ...
(Date:1/14/2014)... 13, 2014 Bob Hainsey, a semiconductor ... 20 years in the industry, has joined SPIE, ... will serve as the society’s Science and Technology Strategist. ... SPIE as our Technology Strategist, further strengthening the technical ...
Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... Twelve-Week Maintenance DosingBEERSE, Belgium, Jan. 22 ... a new class of biologics, has been approved by ... approved indication of ustekinumab is for the treatment of ... to respond to, or who have a contraindication to, ...
... Cell Innovations, Inc., (SCLL.PK) announced today that it has filed a new ... cells. , ... Houston, TX (PRWEB) January 22, 2009 -- Stem Cell ... application for the production of pluripotent stem cells from primordial germ cells. ...
... for testing the quality of a sperm before it ... conception. , Researchers at the University of Edinburgh, funded ... have created a way of chemically ,fingerprinting, individual sperm ... consider whether the sperm is healthy enough to be ...
Cached Biology Technology:New Biologic STELARA(TM) Receives Approval in Europe for Treatment of Moderate to Severe Plaque Psoriasis 2New Biologic STELARA(TM) Receives Approval in Europe for Treatment of Moderate to Severe Plaque Psoriasis 3New Biologic STELARA(TM) Receives Approval in Europe for Treatment of Moderate to Severe Plaque Psoriasis 4Stem Cell Innovations, Inc., Files New Patent Application 2Stem Cell Innovations, Inc., Files New Patent Application 3New sperm shaker to improve IVF success 2
(Date:4/22/2014)... Coral Gables, Fla. (April 21, 2014) -- There are ... out their feathers and spread their colorful tails; satin ... them with blue and shiny objects; and European bitterling ... Each species has evolved a unique method to communicate ... "Signaling can have profound fitness ...
(Date:4/22/2014)... FL, April 22, 2014 Scientists from the Florida ... a protein complex that plays a critical but previously ... The study, which showed a novel role for a ... in the journal eLife , a publisher supported ... Society and the Wellcome Trust. , "This is a ...
(Date:4/22/2014)... Ltd.,s nanotechnology expert will present a poster ... the 7th International Nanotoxicology Congress to be ... Dr. Monita Sharma will outline a strategy consistent with ... Sciences, " Toxicity Testing in the 21st Century: A ... non-animal methods involving human cells and cell lines for ...
Breaking Biology News(10 mins):Best practices in communication for the animal world 2Best practices in communication for the animal world 3Scientists identify critical new protein complex involved in learning and memory 2
... jerks its head uncontrollably for no apparent reason. There ... people, most notably trigeminal neuralgia, and headshaking in horses. ... and treating the condition in horses, the pathology of ... A recent study led by academics ...
... PARSIPPANY, NJ (November 14, 2012) Parents may have some ... study, funded by Pinnacle Foods, Birds Eye brand and published ... to the plate led to more positive evaluations of both ... vegetables with dinner, participants believed the main course would taste ...
... lung cancer research team reports that lung cancer stem ... offering a new avenue for investigating immunotherapy treatment options ... Morris, MD, and his colleagues report their findings in ... , a peer-reviewed online publication that features original research ...
Cached Biology News:Study investigates headshaking in horses 2New study reveals more inspiring reasons to serve veggies at dinner 2Stem cell finding could advance immunotherapy for lung cancer 2
Rabbit polyclonal to Glutathione S Transferase alpha ( Abpromise for all tested applications). Antigen: Full length protein: Human Glutathione S Transferase alpha. Entrez GeneID: 2938 Swi...
Anti-Mouse IgM Heavy Chain:FITC, Clone LO-MM-9, Monoclonal Antibody...
Rabbit polyclonal to FOXJ2 ( Abpromise for all tested applications). entrezGeneID: 55810 SwissProtID: Q9P0K8...
Goat polyclonal to HSPC150 ( Abpromise for all tested applications). entrezGeneID: 29089...
Biology Products: